Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review

Abstract

Prostate cancer is the most common cancer in men. Docetaxel is a common chemotherapeutic agent that has proven its efficacy in the treatment of patients with both castration sensitive and resistant metastatic prostate cancer. We report a case of acute respiratory distress syndrome (ARDS) in a patient with metastatic prostate cancer treated with docetaxel (Taxotere). ARDS is very rare but life threatening complication of docetaxel which requires aggressive supportive care and close monitoring. Better awareness and prompt diagnosis of this treatment related ARDS will improve the effectiveness and outcome of its management.

Academic Editor:Fumitaka Koga

Division of Hematology-Oncology, Department of Medicine, Joan C. Edwards School of Medicine, Marshall University, Edward Comprehensive Care Center, Huntington, WV 25701, USA

Received 23 May 2015; Revised 28 July 2015; Accepted 29 July 2015; 13 August 2015

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

We present a case of acute respiratory distress syndrome in a patient with metastatic prostate cancer treated with docetaxel (Taxotere). Docetaxel is a common chemotherapeutic agent used in the treatment of patients with castration resistant and sensitive metastatic prostate cancer. Docetaxel has many adverse reactions but acute respiratory distress syndrome (ARDS) is relatively rare and life threatening complication. There are very few case reports of ARDS after administration of docetaxel; however in those cases, docetaxel was given in combination with gemcitabine, an agent that has also been reported to cause ARDS in the past.

2. Case Presentation

We report a 74-year-old white male who was diagnosed with de novo metastatic prostate cancer. He was started on concurrent hormonal therapy (Lupron) with docetaxel (based on the ECOG 3805 trial). The dose of docetaxel was reduced due to neuropathy. After cycle # 3 of chemotherapy, he presented to the emergency room with fever, fatigue, and generalized weakness. He had a chest X-ray that showed "bilateral lower lobe atelectasis versus infiltrate." Labs showed absolute neutrophil count of 200 cells/μ L and platelets 67,000 cells/μ L. Treatment was initiated with empiric cefepime and vancomycin.

CT of the chest in Figure 1 was done for further evaluation and was consistent with pulmonary edema. There was no infiltrate to suggest acute pneumonia. He had no history of cardiac disease or congestive heart failure prior to starting chemotherapy. He became hypoxic on the third day of admission. Echo was obtained that showed preserved ejection fraction. Diuresis was initiated with Lasix but patient's respiratory status did not improve. Blood, urine, and sputum cultures were all negative and no other source of infection was found. He was subsequently transferred to the ICU and required intubation for persistent hypoxemia. Chest X-ray showed worsening diffuse bilateral edema. PaO₂ /FIO₂ ratio was >200 mmHg suggestive of acute respiratory distress syndrome. The patient was started on high dose steroid and continued on supportive management. He became more awake and alert. The patient was eventually extubated and started on Continuous Positive Airway Pressure (CPAP). Weaning was unsuccessful and he needed continuous CPAP. The patient did not want further aggressive management and requested palliative care. He eventually enrolled in hospice program.

Figure 1: Diffuse ground glass opacities, pulmonary edema. There are small bilateral pleural effusions.

[figure omitted; refer to PDF]

3. Discussion

Prostate cancer, the most common cancer in men, accounts for 220,800 cases and approximately 27,540 expected deaths per year in the United States for 2015 [1]. The spectrum of advanced systemic disease ranges from pathologically identified locoregional nodal metastases at the time of radical prostatectomy to widespread systemic involvement. The bone, pelvis, and abdominal lymph nodes are the most common sites of metastatic disease. The five-year overall survival in metastatic prostate cancer is 28 percent [1].

Androgen deprivation therapy (ADT) is historically a standard part of the initial approach for patients with metastatic prostate cancer. On the other hand chemotherapy like docetaxel has been reserved for patients who have progressed on ADT [2]. The SWOG 9916 trial [3] and TAX327 trial [4] were the pioneer in showing a survival advantage with chemotherapy in metastatic prostate cancer favoring docetaxel group. The results of two large randomized trials have changed the role of chemotherapy considerably in 2004 in patients with castration resistant metastatic prostate cancer treated with docetaxel-based chemotherapy by demonstrating an overall improvement in survival.

Investigators from the SWOG 9916 trial randomized patients to receive mitoxantrone plus prednisone versus docetaxel (60 mg/m² ) plus estramustine (Emcyt) and dexamethasone every 3 weeks. This trial demonstrated a survival benefit of 2 to 3 months in the docetaxel arm.

Tannock et al. showed a similar survival benefit of 3 months in another international randomized phase III trial (TAX327). The patients were randomized to receive docetaxel (at 75 mg/m² ) plus prednisone given every 3 weeks compared with mitoxantrone and prednisone. These trials led to various studies in which the role of docetaxel was evaluated in combination with newer agents [5-7]. A recent early analysis of ECOG-led phase III randomized trial has shown improved survival in men with castration sensitive metastatic prostate cancer ( [figure omitted; refer to PDF] ) and a high metastatic burden (visceral disease, high bone burden) who received six cycles of docetaxel given at the start of standard ADT compared with patients who received ADT alone. The upfront combination chemohormonal therapy produced a statistically and clinically significant improvement in overall survival compared with ADT alone (52.7 versus 42.3 months with [figure omitted; refer to PDF] value 0.0006, Hazard ratio 0.63 (0.48, 0.82)) [8]. The median OS had not been reached in men with low-volume disease at the time of the analysis.

The taxanes, paclitaxel (Taxol), and docetaxel (Taxotere) have demonstrated their effectiveness as first-line treatment setting for metastatic breast, lung, ovarian, and GI cancers in many randomized clinical trials. They have emerged as important and widely prescribed chemotherapeutic agents exhibiting broad range of antitumor activities [9-13].

Paclitaxel was isolated in 1971 from the Pacific yew (Taxus brevifolia ) whereas docetaxel, a second-generation semisynthetic taxane analogue from the European yew (Taxus baccata ), was identified in the 1980s. These antimicrotubulin drugs act mostly in M phase of the cell cycle. They interfere with the normal function of microtubule growth, by hyperstabilizing their structure resulting in inhibition of DNA, RNA, and protein synthesis [14].

The lung is a frequent target and a common form of iatrogenic injury due to antineoplastic agents [15, 16]. Antineoplastic related lung toxicity has a wide spectrum that varies from interstitial pneumonitis, organizing pneumonia, radiation recall pneumonitis, and nonthromboembolic pulmonary hypertension to diffuse alveolar damage, alveolar hemorrhage, and noncardiogenic pulmonary edema [17-22]. The common patterns of taxane related lung toxicity vary from diffuse interstitial pneumonitis to relatively rare capillary leakage that could be life threatening. Docetaxel has been associated with fluid retention manifested as peripheral edema, pleural effusion, and ascites [23, 24]. The fluid retention is a cumulative-dose process that is delayed by administration of corticosteroids [25]. Noncardiogenic pulmonary edema has been reported with docetaxel [26, 27]; however in both cases docetaxel was given in combination with gemcitabine, an agent that has also been reported to cause ARDS in the past [28]. It was not clear in the above case reports if ARDS was associated with a single agent or was the consequence of a synergy between the two chemotherapeutic drugs. Above, we have described a case of a patient on docetaxel who experienced ARDS without any other discernible causes. Infection had been effectively ruled out and there was no evidence of trauma or heart failure. Respiratory symptoms started within one week of chemotherapy. Our patient received docetaxel as sole chemotherapeutic agent [26, 27]. Gonadotropin-releasing hormone (GnRH) agonist (Lupron) was continued in our patient as hormonal therapy along with the docetaxel. Hormone therapy usually does not cause ARDS; however there is one case report published in 1995 in which patient developed ARDS after injection of leuprorelin [29]. It is unclear if the combination of hormonal therapy with docetaxel contributed to the development of ARDS.

The management of drug induced ARDS required early recognition of pulmonary toxicity and discontinuation of chemotherapy like taxane along with prompt initiation of high dose corticosteroid and diuretic and supportive care. These patients need aggressive supportive care and close monitoring [30]. Bringing awareness of cases such as these may help haste the diagnosis of other patients presenting with similar signs and symptoms, therefore aiding in a quicker recovery.

Conflict of Interests

The authors declare that they have no competing interest.

References

[1] R. L. Siegel, K. D. Miller, A. Jemal, "Cancer statistics, 2015," CA Cancer Journal for Clinicians , vol. 65, no. 1, pp. 5-29, 2015.

[2] D. A. Loblaw, K. S. Virgo, R. Nam, M. R. Somerfield, E. Ben-Josef, D. S. Mendelson, R. Middleton, S. A. Sharp, T. J. Smith, J. Talcott, M. Taplin, N. J. Vogelzang, J. L. Wade III, C. L. Bennett, H. I. Scher, "Initial hormonal management of Androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline," Journal of Clinical Oncology , vol. 25, no. 12, pp. 1596-1605, 2007.

[3] I. F. Tannock, R. de Wit, W. R. Berry, J. Horti, A. Pluzanska, K. N. Chi, S. Oudard, C. Theodore, N. D. James, I. Turesson, M. A. Rosenthal, M. A. Eisenberger, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer," The New England Journal of Medicine , vol. 351, no. 15, pp. 1502-1512, 2004.

[4] D. P. Petrylak, C. M. Tangen, M. H. A. Hussain, P. N. Lara Jr., J. A. Jones, M. E. Taplin, P. A. Burch, D. Berry, C. Moinpour, M. Kohli, M. C. Benson, E. J. Small, D. Raghavan, E. D. Crawford, "Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer," The New England Journal of Medicine , vol. 351, no. 15, pp. 1513-1520, 2004.

[5] C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, L. Collette, D. Lacombe, C. de Balincourt, S. Deleu, J. Rapion, A. T. Van Oosterom, T. M. de Reijke, M. De Santis, A. Verbaeys, F. Ringeisen, J. Bellmunt, P. Albers, F. Calais-da-Silva, "Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer," Annals of Oncology , vol. 20, no. 7, pp. 1264-1269, 2009.

[6] W. K. Kelly, S. Halabi, M. Carducci, D. George, J. F. Mahoney, W. M. Stadler, M. Morris, P. Kantoff, J. P. Monk, E. Kaplan, N. J. Vogelzang, E. J. Small, "Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401," Journal of Clinical Oncology , vol. 30, no. 13, pp. 1534-1540, 2012.

[7] D. I. Quinn, C. M. Tangen, M. Hussain, "SWOG S0421: phase III study of docetaxel (D) and atrasentan (A) versus docetaxel and placebo (P) for men with advanced castrate resistant prostate cancer (CRPC),", supplement 15, article 4511 Journal of Clinical Oncology , vol. 30, 2012.

[8] C. Sweeney, Y.-H. Chen, M. A. Carducci, "Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): an ECOG-led phase III randomized trial,", supplement 5, abstract LBA2 Journal of Clinical Oncology , vol. 32, 2014.

[9] M. J. Edelman, "Novel taxane formulations and microtubule-binding agents in non-small-cell lung cancer,", supplement 1 Clinical Lung Cancer , vol. 10, pp. S30-S34, 2009.

[10] K. L. Hennenfent, R. Govindan, "Novel formulations of taxanes: a review. Old wine in a new bottle?," Annals of Oncology , vol. 17, no. 5, pp. 735-749, 2006.

[11] W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, J. O'Shaughnessy, "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer," Journal of Clinical Oncology , vol. 23, no. 31, pp. 7794-7803, 2005.

[12] M. Harries, C. Moss, T. Perren, M. Gore, G. Hall, M. Everard, R. A'Hern, I. Gibbens, A. Jenkins, R. Shah, C. Cole, O. Pizzada, S. Kaye, "A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer," British Journal of Cancer , vol. 91, no. 4, pp. 627-632, 2004.

[13] M. L. Hensley, J. A. Blessing, R. Mannel, P. G. Rose, "Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial," Gynecologic Oncology , vol. 109, no. 3, pp. 329-334, 2008.

[14] J. Gligorov, J. P. Lotz, "Preclinical pharmacology of the taxanes: implications of the differences,", supplement 2 The Oncologist , vol. 9, pp. 3-8, 2004.

[15] E. C. Rosenow III, A. H. Limper, "Drug-induced pulmonary disease," Seminars in Respiratory Infections , vol. 10, no. 2, pp. 86-95, 1995.

[16] L. S. Snyder, M. I. Hertz, "Cytotoxic drug-induced lung injury," Seminars in Respiratory Infections , vol. 3, no. 3, pp. 217-228, 1988.

[17] U. Jehn, N. Göldel, R. Rienmüller, W. Wilmanns, "Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia," Medical Oncology and Tumor Pharmacotherapy , vol. 5, no. 1, pp. 41-47, 1988.

[18] J. H. Ryu, "Chemotherapy-induced pulmonary toxicity in lung cancer patients," Journal of Thoracic Oncology , vol. 5, no. 9, pp. 1313-1314, 2010.

[19] B. Vahid, P. E. Marik, "Pulmonary complications of novel antineoplastic agents for solid tumors," Chest , vol. 133, no. 2, pp. 528-538, 2008.

[20] M. Joerger, A. Gunz, R. Speich, B. C. Pestalozzi, "Gemcitabine-related pulmonary toxicity," Swiss Medical Weekly , vol. 132, no. 1-2, pp. 17-20, 2002.

[21] J. Watkins, J. H. Slade, A. Phan, C. Eng, A. Weissferdt, M. J. Overman, "Fatal diffuse alveolar damage associated with oxaliplatin administration," Clinical Colorectal Cancer , vol. 10, no. 3, pp. 198-202, 2011.

[22] C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, K. Zervas, "Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: a pilot study," Annals of Oncology , vol. 19, no. 10, pp. 1765-1769, 2008.

[23] D. Schrijvers, J. Wanders, L. Dirix, A. Prove, I. Vonck, A. Van Oosterom, S. Kaye, "Coping with toxicities of docetaxel (Taxotere)," Annals of Oncology , vol. 4, pp. 610-611, 1993.

[24] M. E. Trudeau, E. A. Eisenhauer, B. P. Higgins, F. Letendre, W. S. Lofters, B. D. Norris, T. A. Vandenberg, F. Delorme, A. M. Muldal, "Docetaxel in patients with metastatic breast cancer a phase ii study of the national cancer institute of canada-clinical trials group," Journal of Clinical Oncology , vol. 14, no. 2, pp. 422-428, 1996.

[25] M. J. Piccart, J. Klijn, R. Paridaens, M. Nooij, L. Mauriac, R. Coleman, M. Bontenbal, A. Awada, J. Selleslags, A. Van Vreckem, M. Van Glabbeke, "Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the european organization for research and treatment of cancer investigational drug branch for breast cancer," Journal of Clinical Oncology , vol. 15, no. 9, pp. 3149-3155, 1997.

[26] E. Briasoulis, N. Pavlidis, "Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy," The Oncologist , vol. 6, no. 2, pp. 153-161, 2001.

[27] M. L. Dunsford, G. M. Mead, A. C. Bateman, T. Cook, K. Tung, "Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma," Annals of Oncology , vol. 10, no. 8, pp. 943-947, 1999.

[28] A. Bonnichon, L. Vedrine, M. Aletti, S. Le Moulec, M. Borne, J. Margery, O. Bauduceau, M. Fayolle, B. Ceccaldi, "Favorable outcome of gemcitabine-induced acute respiratory distress syndrome," Revue de Pneumologie Clinique , vol. 63, no. 6, pp. 379-383, 2007.

[29] L. Gamelin, S. Jeanson, F. Chenue, "Acute respiratory distress syndrome after injection of leuprorelin," Therapie , vol. 50, no. 6, pp. 587-588, 1995.

[30] P. Zappasodi, R. Dore, C. Castagnola, C. Astori, M. Varettoni, S. Mangiacavalli, M. Lazzarino, A. Corso, "Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma," Journal of Clinical Oncology , vol. 25, no. 22, pp. 3380-3381, 2007.